Certara, Inc. (CERT) - Q1 2026 10-Q Summary
Business Context and Reporting Period
Certara, Inc. is a global leader in biosimulation science, technology, and consulting services for the biopharmaceutical industry, utilizing Model-Informed Drug Development (MIDD). This report covers the quarterly period ended March 31, 2026. The Company operates as a single reportable segment, providing software products and technology-driven services to optimize drug discovery and regulatory submissions.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $106.9 million | $106.0 million |
| Net Income (Loss) | $(8.8) million | $4.7 million |
| Adjusted EBITDA | $31.7 million | $34.8 million |
| Operating Cash Flow | $11.7 million | $17.4 million |
| Cash and Equivalents | $149.5 million | $189.4 million (Dec 31, 2025) |
| Total Debt (Principal) | $294.8 million | $295.5 million (Dec 31, 2025) |
| Revolving Credit Availability | $100.0 million | $100.0 million |
| Diluted EPS | $(0.06) | $0.03 |
Material Changes vs. Prior Period
- Revenue: Increased 1% ($0.9 million) year-over-year. Software revenue grew 7% to $49.7 million, while Services revenue declined 4% to $57.2 million due to lower revenue from a previously acquired business.
- Profitability: The Company reported a net loss of $8.8 million compared to net income of $4.7 million in Q1 2025. This swing was primarily driven by a $12.7 million increase in operating expenses.
- Expenses: General and Administrative (G&A) expenses surged 49% to $29.4 million. This increase was largely attributable to a $7.4 million rise in business acquisition contingent consideration expense and $1.0 million in executive recruiting costs.
- Stock Repurchases: The Company repurchased 5.8 million shares for $40.0 million under its authorized program, significantly impacting financing cash flows.
Guidance, Outlook, and Material Events
- Divestiture Completed: On May 8, 2026 (subsequent to the reporting period), Certara completed the sale of its global medical writing and regulatory services business to Veristat, LLC. The transaction includes $85 million in cash consideration, $15 million in escrow, and a potential $35 million earn-out. Management expects to recognize a loss on the transaction ranging from approximately $28.9 million to $53.7 million.
- Strategic Focus: Proceeds from the divestiture will be used for general corporate purposes. The Company aims to strengthen its focus on core operations and accelerate AI-integrated modeling and simulation.
- Key Performance Indicators: Q1 2026 bookings were $115.3 million (down from $118.2 million in Q1 2025). Net retention rates improved to 106.1% from 102.4%.
- Risks: Key risks include the potential failure of the divestiture to close (now mitigated by completion), deceleration in MIDD adoption, customer R&D spending cuts, and cybersecurity threats.
Investor Verification Checklist
- Verify the final loss amount recognized on the Veristat divestiture once working capital adjustments and earn-out terms are finalized.
- Monitor the impact of the $7.4 million contingent consideration expense on future G&A trends and whether this is a recurring item.
- Assess the sustainability of the 106.1% net retention rate given the decline in bookings.
- Review the Company's ability to maintain positive operating cash flow given the significant cash outflow from stock repurchases ($40 million in Q1).
- Confirm the integration of AI capabilities into the core product portfolio as a driver for future software revenue growth.